A 28-year-old woman with type 1 diabetes using insulin degludec complains of recurrent hypoglycemic episodes before breakfast despite adequate meal planning. Compared to insulin glargine, what pharmacokinetic property of degludec REDUCES this risk?

• A Shorter duration of action of 18–20 hours compared to glargine's 12–14 hours
• B Rapid onset allowing precise mealtime dosing unlike the slow onset of glargine
• C Renal clearance rather than enzymatic degradation reducing accumulation
• D Formation of multi-hexameric depot at the injection site resulting in a flat, peakless PK profile with ultra-long duration and lower intra-patient variability ✓

Explanation

Insulin degludec forms multi-hexameric chains (dihexameric chains linked via fatty acid acylation and zinc coordination) that create a large depot at the subcutaneous injection site. This depot slowly dissolves into monomers, producing an ultra-long duration of action (>42 hours) with an extremely flat, almost peakless pharmacokinetic profile. Crucially, degludec has significantly lower day-to-day intra-patient pharmacokinetic variability (~20%) compared to insulin glargine (~48%), which is the primary reason for fewer nocturnal/early morning hypoglycemic episodes. Glargine's duration is approximately 20–24 hours, not 12–14 hours. Degludec is not a rapid-acting insulin.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.